Optical News

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for p...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Be...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved....

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 4:00 p.m. Central Time. A live webcast of the presentation will be available in the “Investors” section of the Company’s website at www.ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event....

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY), a lifestyle brand focused on vision for all, today unveiled its first Intelligent Eyewear frame designed for all-day, everyday wear. The debut style combines Warby Parker’s distinctive approach to design with Google’s leadership in AI and Samsung’s mobile leadership to create beautifully crafted eyewear that seamlessly enhances everyday life. For more than 16 years, Warby Parker has redefined how consumers shop for glasses by pairing me...

DURHAM, N.C.--(BUSINESS WIRE)--Lexitas Pharma Services, a portfolio company of QHP Capital, is pleased to announce the closing of its acquisition of Erie Retina Research—one of the nation’s premier retina research centers led by Dr. David Almeida, MD, MBA, PhD—which will operate as a wholly owned subsidiary of Lexitas. As part of the transaction, Lexitas also acquired CASExERIE, LLC, an ophthalmic innovation hub specializing in advanced research, surgical training, and retina-focused product de...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex.* Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the mos...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assembl...